Kooth vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 52)
Kooth logo

Kooth

ChallengerHealthcare

Digital Mental Health & Wellbeing Platform for Young People

Kooth is a publicly traded UK digital mental health company (AIM: KOO) providing NHS-commissioned mental health services for under-18s; 2025 revenues of £63.3M; serves 20M+ people in the US and UK; operates in 3 U.S.

AI VisibilityBeta
Overall Score
C52
Category Rank
#279 of 596
AI Consensus
90%
Trend
stable
Per Platform
ChatGPT
57
Perplexity
58
Gemini
55

About

Kooth Digital Health is a UK-based digital mental health and wellbeing company founded in 2001, incorporated as a private limited company and publicly listed on the London Stock Exchange AIM market under the ticker KOO. Kooth is the largest single-access provider of digital mental health services for children and young people under 18 in NHS England, providing free, accessible, clinically robust support with no waiting lists. The platform gives young people aged 11 to 25 access to an online community of peers, structured self-help content, and a team of experienced counsellors — available through web and mobile, with no referral required.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

52
Overall Score
90
#279
Category Rank
#2
90
AI Consensus
83
stable
Trend
stable
57
ChatGPT
92
58
Perplexity
93
55
Gemini
89
55
Claude
96
54
Grok
95

Key Details

Category
Digital Mental Health & Wellbeing Platform for Young People
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.